Product
Miricorilant
Aliases
CORT118335
6 clinical trials
6 indications
Indication
Nonalcoholic SteatohepatitisIndication
Weight GainIndication
Non-alcoholic Steatohepatitis (NASH)Indication
Antipsychotic-induced Weight GainIndication
Alcohol Use DisorderClinical trial
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Miricorilant in Adult Patients With Nonalcoholic Steatohepatitis/Metabolic Dysfunction-Associated Steatohepatitis (MONARCH)Status: Recruiting, Estimated PCD: 2025-12-01
Clinical trial
A Phase 1, Open-Label, Fixed-Sequence Crossover Study to Evaluate the Effect of a Strong Inhibitor of Cytochrome P450 2C19 on the Pharmacokinetics of Miricorilant in Healthy SubjectsStatus: Completed, Estimated PCD: 2023-02-23
Clinical trial
A Phase 1b, Open-Label Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Adult Patients With Presumed Nonalcoholic Steatohepatitis (NASH)Status: Recruiting, Estimated PCD: 2024-08-01
Clinical trial
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant (CORT118335) in Obese Adult Patients With Schizophrenia or Bipolar Disorder and Recent Weight Gain While Taking Antipsychotic Medications (GRATITUDE)Status: Completed, Estimated PCD: 2022-12-31
Clinical trial
Medication Development for Protracted Abstinence in Alcoholism: CORT118335 Versus PlaceboStatus: Completed, Estimated PCD: 2022-04-15
Clinical trial
A Phase 1, Open-label, Single-dose, Adaptive Design Study to Evaluate the Effects of Hepatic Impairment on the Pharmacokinetics of MiricorilantStatus: Recruiting, Estimated PCD: 2024-12-31